Literature DB >> 33911390

Genotype-Phenotype Correlations in MPAN Due to C19orf12 Variants.

Josef Finsterer1.   

Abstract

Entities:  

Year:  2020        PMID: 33911390      PMCID: PMC8061527          DOI: 10.4103/aian.AIAN_383_20

Source DB:  PubMed          Journal:  Ann Indian Acad Neurol        ISSN: 0972-2327            Impact factor:   1.383


× No keyword cloud information.
The Editor, With interest, we read the article by Incecik et al. about six Turkish patients with mitochondrial membrane protein-associated neurodegeneration (MPAN) due to the variants c.371_372insT (patient 1 and 5) and c. 166_167insG (patients 2, 3, and 4) in C19orf12.[1] It was concluded that patients with neurodegeneration with brain iron accumulation (NBIA) manifesting with cognitive decline, optic atrophy, motor axonal neuropathy, and psychiatric abnormalities but without the “eye of the tiger sign” should be screened for mutations in C19orf12.[1] We have the following comments and concerns. The main shortcoming of the study is that patient 6 was diagnosed with MPAN without confirmation of a C19orf12 mutation. Diagnosing MPAN solely upon the clinical presentation, nerve conduction studies, and the cerebral MRI is inappropriate. Furthermore, there are cases in which the genotype–phenotype correlation is poor due to questionable pathogenicity of a suspicious C19orf12 variant.[2] Thus, patient 6 should be excluded from the evaluation. Missing is the therapeutic management of the presented patients. Since patient 1 presented with some features of Parkinsonism [Table 1],[1] we should know if anti-Parkinson medication was applied and if it had a beneficial effect. It should be mentioned which therapy patients 1, 2, 4, 5, and 6 received for spasticity and dystonia and if these measures reduced dystonia and spasticity.
Table 1

Clinical manifestations in the 5 patients with genetically confirmed MPAN

FeatureP1P2P3P4P5
Age (years)1412np1717
Sex (m/f)Mfmff
Consanguineous parents+++npnp
C19orf12 variant+++++
Homozygosityyesyesyesyesyes
Onset age (years)109np10np
Gait disturbance+++++
Behavioural disturbance---++
Cognitive impairment+--++
Dysarthria++--+
Dyskinesia+----
Hypomimia+----
Bradykinesia+--+-
Intentional tremor++--+
Spasticity++-++
Dystonia++-++
Optic atrophy---++
Axonal neuropathy---+np
HI of GP + SN++++np

M=Male, f=Female, np=Not provided, HI=Hypointensity, GP=Globus pallidus, SN=Substantia nigra

Clinical manifestations in the 5 patients with genetically confirmed MPAN M=Male, f=Female, np=Not provided, HI=Hypointensity, GP=Globus pallidus, SN=Substantia nigra Patient 2, 3, and 4 carried the same mutation. Nonetheless, their phenotype varied considerably [Table 1]. Also patients 1 and 5 carried the same variant but their phenotype was different [Table 1]. The only phenotypic feature present in each patient was gait disturbance. Five patients had spasticity and dystonia, respectively [Table 1]. An explanation for this phenotypic heterogeneity between patients carrying the same variants should be provided. There are indications that C19orf12 variants may manifest clinically even if they occur in the heterozygous form.[3] We thus should know if any relatives of the 6 index patients carried any of the described variants in the heterozygous form and manifested clinically. Did any relative present with the allelic variant of MPANSPG43? [4] A thorough family history of the 6 patients is mandatory. In a previous study of 15 Turkish patients, mean age at onset of symptoms was 24.5 years (range 10–36), thus much later than in the six index patients [Table 1].[5] It should be discussed if MPAN should be divided into an early-onset and late-onset form and if there is genetic or phenotypic difference between these two categories of MPAN. In another previous study cerebellar atrophy has been reported.[6] We should know if intentional tremor, dysarthria, and gait disturbance were attributable to cerebellar involvement rather than affection of the globi pallidi or the substantia nigra. It would be interesting to know if any MR-spectroscopy investigations were carried out to see if there was increased lactate in the cerebrospinal fluid or if there was iron overload in the basal ganglia. Overall, this study has some shortcomings and limitations which need to be solved before drawing final conclusions. MPAN should be diagnosed only in the presence of a pathogenic C19orf12 variant. Family history and investigation of first-degree relatives is a prerequisite for determining the trait of inheritance and to find out if heterozygosity manifests clinically.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  6 in total

1.  The p.Thr11Met mutation in c19orf12 is frequent among adult Turkish patients with MPAN.

Authors:  Simone Olgiati; Okan Doğu; Zeynep Tufekcioglu; Yunus Diler; Esen Saka; Murat Gultekin; Hakan Kaleagasi; Demy Kuipers; Josja Graafland; Guido J Breedveld; Marialuisa Quadri; Reyhan Sürmeli; Gülin Sünter; Tuğrul Doğan; Ayşe Destina Yalçın; Başar Bilgiç; Bülent Elibol; Murat Emre; Hasmet A Hanagasi; Vincenzo Bonifati
Journal:  Parkinsonism Relat Disord       Date:  2017-03-21       Impact factor: 4.891

2.  Clinical and genetic spectrum of an orphan disease MPAN: a series with new variants and a novel phenotype.

Authors:  Nihan Hande Akçakaya; Garen Haryanyan; Sevcan Mercan; Nejla Sozer; Asuman Ali; Temel Tombul; Ugur Ozbek; Sibel Aylin Uğur İşeri; Zuhal Yapıcı
Journal:  Neurol Neurochir Pol       Date:  2019-12-05       Impact factor: 1.621

3.  Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12.

Authors:  Guida Landouré; Peng-Peng Zhu; Charles M Lourenço; Janel O Johnson; Camilo Toro; Katherine V Bricceno; Carlo Rinaldi; Katherine G Meilleur; Modibo Sangaré; Oumarou Diallo; Tyler M Pierson; Hiroyuki Ishiura; Shoji Tsuji; Nichole Hein; John K Fink; Marion Stoll; Garth Nicholson; Michael A Gonzalez; Fiorella Speziani; Alexandra Dürr; Giovanni Stevanin; Leslie G Biesecker; John Accardi; Dennis M D Landis; William A Gahl; Bryan J Traynor; Wilson Marques; Stephan Züchner; Craig Blackstone; Kenneth H Fischbeck; Barrington G Burnett
Journal:  Hum Mutat       Date:  2013-08-12       Impact factor: 4.878

4.  "Eye of tiger sign" mimic in an adolescent boy with mitochondrial membrane protein associated neurodegeneration (MPAN).

Authors:  Sangeetha Yoganathan; Sniya Valsa Sudhakar; Maya Thomas; Atanu Kumar Dutta; Sumita Danda
Journal:  Brain Dev       Date:  2015-11-18       Impact factor: 1.961

5.  Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN).

Authors:  Allison Gregory; Mitesh Lotia; Suh Young Jeong; Rachel Fox; Dolly Zhen; Lynn Sanford; Jeff Hamada; Amir Jahic; Christian Beetz; Alison Freed; Manju A Kurian; Thomas Cullup; Marlous C M van der Weijden; Vy Nguyen; Naly Setthavongsack; Daphne Garcia; Victoria Krajbich; Thao Pham; Randy Woltjer; Benjamin P George; Kelly Q Minks; Alexander R Paciorkowski; Penelope Hogarth; Joseph Jankovic; Susan J Hayflick
Journal:  Mol Genet Genomic Med       Date:  2019-05-13       Impact factor: 2.183

6.  Mitochondrial Membrane Protein-Associated Neurodegeneration: A Case Series of Six Children.

Authors:  Faruk Incecik; Ozlem M Herguner; Atil Bisgin
Journal:  Ann Indian Acad Neurol       Date:  2019-09-17       Impact factor: 1.383

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.